Skip to contentN
NovoCure Ltd
N
NVCRNovoCure Ltd Q1 2019 · 10-Q
Revenue$73.31M$73.31M+40.6% vs Q1 2018 Net Income-$12.15M-$12.15MN/M vs Q1 2018 EPS Diluted-$0.13-$0.13N/M vs Q1 2018 Gross Profit$53,495,000+57.9% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
NovoCure Ltd · CIK 1645113 · Engraved from SEC EDGAR
Operating Cash Flow-$4,315,000N/M Free Cash Flowderived-$6,640,000N/M Margins · derivedGross margin73.0%+8.0 pt vs Q1 2018
Operating margin-8.3%+16.0 pt vs Q1 2018
Net margin-16.6%+23.2 pt vs Q1 2018
ended Mar 31, 2019 · filed May 2, 2019 · 32 d after period end